Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

Monday December 14, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, FDA, COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion.Ampio_logoUSE 

The company entered into a collaborative research agreement with the oldest and one of the top children's hospitals in the United States whereby both parties will work together and conduct exploratory research to determine whether the anti-inflammatory and signaling pathways of Ampion could play a role in the treatment of certain rare inflammatory pediatric diseases.

Currently in clinical trials for treatment of inflammation due to osteoarthritis and COVID-19 related acute respiratory distress syndrome (ARDS), Ampion has been shown to reduce inflammation through multiple pathways.

The exploratory research conducted under the collaborative research agreement will utilize cell culture models and proteomic, metabolomic, genomic and in silico computational methods as well as in vitro characterization of identified dysregulated signaling pathways in human cultured cell types (e.g. human epithelial cells, microvascular endothelial cells, peripheral blood mononuclear cells (PBMC)).

Dr. Andrew Terker, a prominent basic research scientist specializing in kidney research at Vanderbilt University Medical Center, has entered into a research collaboration with Ampio in which the immunology based anti-inflammatory properties of Ampion will be investigated as a treatment for acute and chronic kidney disease, extremely common conditions for which new therapies are needed.

Dr. Terker's interest in exploring Ampion's anti-inflammatory effects in acute kidney injury (AKI) and chronic kidney disease (CKD) is based on more than a dozen peer-reviewed publications that reported Ampion modulates anti-inflammatory signaling pathways known to be relevant in kidney disease.

The FDA has approved three different methods of administration of Ampion: by direct intra articular injection, intravenous administration and by inhalation in the course of clinical trials for the treatment of ARDS in COVID-19 patients, COVID-19 patients requiring supplemental oxygen, and osteoarthritis of the knee.

Equally important to Dr. Terker, there have been no drug-related adverse events reported with any method of administration in any Ampion clinical trials, the company said.